logo
Plus   Neg
Share
Email

Seattle Genetics, Astellas, Merck To Evaluate Enfortumab Vedotin Plus KEYTRUDA

Seattle Genetics, Inc. (SGEN) and Astellas Pharma Inc. have entered a clinical collaboration agreement with Merck to evaluate the combination of Seattle Genetics' and Astellas' antibody-drug conjugate enfortumab vedotin and Merck's anti-PD-1 therapy, KEYTRUDA, in patients with previously untreated metastatic urothelial cancer. The companies will conduct a global, registrational phase 3 clinical trial to be led by Seattle Genetics. The companies currently plan to initiate the trial in the first half of 2020.

Enfortumab vedotin is currently under review by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The PDUFA action date is March 15, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT